Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Aktis Oncology announced the presentation of initial clinical imaging and dosimetry data for their radioconjugate AKY-2519 targeting B7-H3 expressing solid tumors at the 2026 ASCO Annual Meeting. The company received FDA clearance to initiate a Phase 1b clinical trial of AKY-2519 mid-2026. AKY-2519 is Aktis's second clinical-stage radioconjugate de…